You can buy Acatinib at the lowest price at Nextgen.ooo online pharmacy. Acalabrutinib is a Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma. Also known as ACP-196, acalabrutinib is also considered a second-generation BTK inhibitor because it has been rationally designed to be more potent and selective than ibrutinib and is theoretically expected to exhibit fewer side effects.
In addition, the drug has been granted Breakthrough Therapy Designation by the FDA. It has also received Orphan Drug status, which provides incentives to aid and encourage the development of drugs for rare diseases. More than 35 clinical trials in 40 countries involving more than 2,500 patients are currently ongoing or have been completed to further study and expand the therapeutic use of acalabrutinib.
 
Mantle cell lymphoma (MCL) is a rare but aggressive type of B-cell non-Hodgkin lymphoma (NHL) with a poor prognosis. Patients with MCL often experience relapse, which ultimately indicates disease progression. Lymphoma occurs when immune system lymphocytes grow and multiply uncontrollably. These cancerous lymphocytes can travel to many parts of the body, including the lymph nodes, spleen, bone marrow, blood, and other organs, where they can multiply and form a mass called a tumor. One of the main types of lymphocytes that can develop into cancerous lymphomas are the body's own B lymphocytes. Bruton tyrosine kinase (BTK) is a signaling molecule of the B-cell antigen receptor and cytokine receptor pathway. This BTK signaling causes activation of pathways necessary for B-cell proliferation, transport, chemotaxis, and adhesion. Acalabrutinib is a small molecule BTK inhibitor. Both acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine ​​residue (Cys481) in the active site of BTK, leading to inhibition of BTK enzymatic activity. As a result, acalabrutinib inhibits BTK-mediated activation of CD86 and CD69 signaling proteins, which ultimately suppress the proliferation and survival of malignant B cells.
 
While ibrutinib is generally recognized as a first-in-class BTK inhibitor, acalabrutinib is considered a second-generation BTK inhibitor primarily because it exhibits higher selectivity and inhibition of BTK target activity with a much higher IC50 and has little or no inhibition of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1 kinases.